|
US4350687A
(en)
|
1980-02-10 |
1982-09-21 |
Research Corporation |
Platelet derived cell growth factor
|
|
JPS60146833A
(ja)
|
1984-01-10 |
1985-08-02 |
Green Cross Corp:The |
モノクロ−ナル抗体製剤
|
|
JPS6178731A
(ja)
|
1985-05-20 |
1986-04-22 |
Green Cross Corp:The |
加熱処理免疫グロブリン製剤
|
|
CA1327161C
(en)
|
1987-09-01 |
1994-02-22 |
Mitsugu Kobayashi |
Lyophilized pharmaceutical composition of neocarzinostatin derivative
|
|
SE8801537D0
(sv)
|
1988-04-26 |
1988-04-26 |
Ellco Food Ab |
Cellodlingsmedium samt forfarande for dess framstellning
|
|
US5252713A
(en)
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
WO1990011091A1
(en)
|
1989-03-27 |
1990-10-04 |
Centocor, Inc. |
FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
|
|
US5116944A
(en)
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
|
US5216130A
(en)
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
PT910382E
(pt)
|
1996-04-26 |
2003-10-31 |
Genaera Corp |
Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
|
|
GB9613182D0
(en)
|
1996-06-24 |
1996-08-28 |
Nycomed Imaging As |
Method
|
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
|
US6416967B2
(en)
|
1996-07-12 |
2002-07-09 |
Precision Therapeutics, Inc. |
Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
|
|
PT1023050E
(pt)
|
1997-06-27 |
2013-12-04 |
Abraxis Bioscience Llc |
Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US7041301B1
(en)
|
1997-11-07 |
2006-05-09 |
Mayo Foundation For Medical Education And Research |
Interferon immunotherapy
|
|
US6616925B1
(en)
|
1998-04-02 |
2003-09-09 |
I.D.M. Immuno-Designed Molecules |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
|
|
US7112409B2
(en)
|
1999-01-29 |
2006-09-26 |
Center For Molecular Medicine And Immunology |
Method of determining cytokine dosage for myelosuppressive state
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US6420378B1
(en)
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
|
DE10132502A1
(de)
|
2001-07-05 |
2003-01-23 |
Gsf Forschungszentrum Umwelt |
Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
|
|
IL164287A0
(en)
|
2002-04-12 |
2005-12-18 |
Medarex Inc |
Methods of treatment using ctla-4 antibodies
|
|
WO2004004658A2
(en)
|
2002-07-09 |
2004-01-15 |
Point Therapeutics, Inc. |
Methods and compositions relating to isoleucine boroproline compounds
|
|
AU2003273299B2
(en)
|
2002-09-05 |
2010-04-01 |
Medimmune, Llc |
Methods of preventing or treating cell malignancies by administering CD2 antagonists
|
|
EP1545204B1
(en)
|
2002-09-06 |
2016-08-10 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
|
EP1585548B1
(en)
|
2002-12-09 |
2018-06-27 |
Abraxis BioScience, LLC |
Compositions and methods of delivery of pharmacological agents
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US8007782B2
(en)
|
2003-10-22 |
2011-08-30 |
The Johns Hopkins University |
Combination bacteriolytic therapy for the treatment of tumors
|
|
EP1763356B1
(en)
|
2004-04-22 |
2008-07-16 |
Eli Lilly And Company |
Composition comprising a survivin antisense oligonucleotide and gemcitabine for the treatment of cancer
|
|
MXPA06013191A
(es)
*
|
2004-05-14 |
2007-07-24 |
Abraxis Bioscience Inc |
Metodos de tratamiento que utilizan proteinas que enlazan albumina como objetivos.
|
|
JP2008510466A
(ja)
*
|
2004-08-19 |
2008-04-10 |
ジェネンテック・インコーポレーテッド |
エフェクター機能が変更しているポリペプチド変異体
|
|
WO2006034455A2
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
|
AU2005294214A1
(en)
|
2004-10-07 |
2006-04-20 |
Emory University |
Multifunctional nanoparticles conjugates and their use
|
|
ES2678448T3
(es)
|
2005-02-18 |
2018-08-10 |
Abraxis Bioscience, Llc |
Combinaciones y modos de administración de agentes terapéuticos y terapia combinada
|
|
US8735394B2
(en)
*
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN101355928B
(zh)
|
2005-04-26 |
2013-05-22 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和方法
|
|
US10183076B2
(en)
|
2005-05-16 |
2019-01-22 |
Resdevco Research And Development Co. L |
Topical compositions for treatment of irritation of mucous membranes
|
|
TWI417114B
(zh)
|
2005-08-31 |
2013-12-01 |
Abraxis Bioscience Llc |
具有增強穩定性之弱水溶性藥物之組合物及其製備方法
|
|
JP5368093B2
(ja)
|
2005-08-31 |
2013-12-18 |
アブラクシス バイオサイエンス， エルエルシー |
増大した安定性を有する難水溶性薬剤の組成物および調製の方法
|
|
US7776832B2
(en)
|
2006-04-21 |
2010-08-17 |
Gem Pharmaceuticals, Llc |
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
|
|
HRP20191115T1
(hr)
|
2006-09-26 |
2019-09-20 |
Genmab A/S |
Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
|
|
EP2081687A2
(en)
|
2006-10-17 |
2009-07-29 |
Koninklijke Philips Electronics N.V. |
Device for amplification and detection of nucleic acids
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100112077A1
(en)
*
|
2006-11-06 |
2010-05-06 |
Abraxis Bioscience, Llc |
Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
|
|
WO2008057561A2
(en)
|
2006-11-07 |
2008-05-15 |
Dow Agrosciences Llc |
Sprayable, controlled-release, male annihilation technique (mat) formulation and insect control method
|
|
US20110262525A1
(en)
|
2006-12-13 |
2011-10-27 |
Schering Corporation |
Methods of treatment
|
|
KR20090118999A
(ko)
|
2007-03-07 |
2009-11-18 |
아브락시스 바이오사이언스, 엘엘씨 |
항암제로서 라파마이신 및 알부민을 포함하는 나노입자
|
|
US20100047234A1
(en)
|
2007-03-14 |
2010-02-25 |
Markovic Svetomir N |
Treating skin cancer
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
GB2465940A
(en)
|
2007-10-01 |
2010-06-09 |
Hospital For Sick Children |
Neural tumor stem cells and methods of use thereof
|
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
|
EP3266453A1
(en)
|
2008-07-03 |
2018-01-10 |
Mayo Foundation for Medical Education and Research |
Treating cancer
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
WO2010017216A2
(en)
|
2008-08-04 |
2010-02-11 |
Allocure |
Mesenchymal stromal cell populations and methods of isolating and using same
|
|
WO2010075540A1
(en)
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
US9636384B2
(en)
|
2009-04-06 |
2017-05-02 |
Mayo Foundation For Medical Education And Research |
Methods for making polymeric nanoparticle-polypeptide complex
|
|
US8571805B2
(en)
|
2009-04-10 |
2013-10-29 |
Pharmaco-Kinesis Corporation |
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
|
|
CA2758200A1
(en)
|
2009-04-10 |
2010-10-14 |
Abraxis Bioscience, Llc |
Nanoparticle formulations and uses thereof
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
EP2435075A2
(en)
|
2009-05-28 |
2012-04-04 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
US8345535B2
(en)
*
|
2009-07-13 |
2013-01-01 |
Lg Electronics Inc. |
Method and apparatus for generating ranging preamble code in wireless communication system
|
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
CA2780130A1
(en)
|
2009-11-05 |
2011-05-12 |
The Uab Research Foundation |
Treating basal-like genotype cancers
|
|
US20120263739A1
(en)
|
2009-11-13 |
2012-10-18 |
Merck Patent Gmbh |
Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
|
|
WO2011066374A2
(en)
*
|
2009-11-24 |
2011-06-03 |
Alder Biopharmaceuticals, Inc. |
Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
EP2533810B1
(en)
*
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
|
KR101850566B1
(ko)
|
2010-06-07 |
2018-04-19 |
아브락시스 바이오사이언스, 엘엘씨 |
증식성 질환의 치료를 위한 조합 치료 방법
|
|
US9466148B2
(en)
|
2010-09-03 |
2016-10-11 |
Disney Enterprises, Inc. |
Systems and methods to dynamically adjust an image on a display monitor represented in a video feed
|
|
WO2012048223A1
(en)
*
|
2010-10-08 |
2012-04-12 |
Abraxis Bioscience, Llc |
Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
|
|
WO2012071554A2
(en)
*
|
2010-11-23 |
2012-05-31 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of oral mucositis
|
|
WO2012088388A2
(en)
|
2010-12-23 |
2012-06-28 |
Mayo Foundation For Medical Education And Research |
Treating multiple myeloma
|
|
PT2707030T
(pt)
|
2011-05-09 |
2020-05-22 |
Mayo Found Medical Education & Res |
Tratamentos de cancro
|
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
|
AU2013201121A1
(en)
|
2011-09-20 |
2013-04-04 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
WO2013071058A1
(en)
|
2011-11-09 |
2013-05-16 |
The Uab Research Foundation |
Her3 antibodies and uses thereof
|
|
EP2893003B1
(en)
|
2012-09-04 |
2021-03-31 |
Inven2 AS |
Selective and controlled expansion of educated nk cells
|
|
US10413606B2
(en)
|
2012-10-01 |
2019-09-17 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
EP3626742A1
(en)
|
2013-09-27 |
2020-03-25 |
F. Hoffmann-La Roche AG |
Anti-pdl1 antibody formulations
|
|
JP6695286B2
(ja)
|
2014-06-13 |
2020-05-20 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
リンパ腫の処置
|
|
KR20170020371A
(ko)
|
2014-06-16 |
2017-02-22 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
골수종의 치료
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
PE20170242A1
(es)
|
2014-10-06 |
2017-03-30 |
Mayo Foundation |
Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
BR112017011536A2
(pt)
|
2014-12-02 |
2018-02-27 |
Celgene Corp |
terapias de combinação
|
|
CN114796130B
(zh)
|
2015-08-18 |
2023-10-20 |
梅约医学教育与研究基金会 |
载体结合剂组合物及其制备和使用方法
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
CA3014531A1
(en)
|
2016-02-12 |
2017-08-17 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
WO2017165439A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for improving the therapeutic index for a chemotherapeutic drug
|
|
EP3432926A4
(en)
|
2016-03-21 |
2019-11-20 |
Mayo Foundation for Medical Education and Research |
METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
JP7158372B2
(ja)
|
2016-08-05 |
2022-10-21 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
癌治療のための修飾抗体－アルブミンナノ粒子複合体
|
|
AU2017321798B2
(en)
|
2016-09-01 |
2023-06-15 |
Mayo Foundation For Medical Education And Research |
Methods and compositions for targeting T-cell cancers
|
|
MX2019002474A
(es)
|
2016-09-01 |
2019-09-18 |
Mayo Found Medical Education & Res |
Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
|
|
WO2018048816A1
(en)
|
2016-09-06 |
2018-03-15 |
Mayo Foundation For Medical Education And Research |
Methods of treating pd-l1 expressing cancer
|
|
EP3509635A1
(en)
|
2016-09-06 |
2019-07-17 |
Vavotar Life Sciences LLC |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
RU2756892C2
(ru)
|
2016-09-06 |
2021-10-06 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
|
|
US11041014B2
(en)
|
2016-10-28 |
2021-06-22 |
S & K Biopharma, Inc. |
Lactoferrin/albumin fusion protein and production method therefor
|